Consolidation of R&D Leads Amgen to Sublease Bay Area Space to Undisclosed Company

Consolidation of R&D Leads Amgen to Sublease Bay Area Space to Undisclosed Company
January 22, 2016
Amgen, the world's largest independent biotech company, is subleasing at least part of 333 Oyster Point Boulevard in South San Francisco to an undisclosed company. The building, leased by Amgen for 15 years, has been vacant since it was constructed in 2008.
MORE ON THIS TOPIC